Scalper1 News
Drugmaker Medivation (MDVN) agreed to acquire a late-stage breast-cancer drug candidate from BioMarin Pharmaceutical (BMRN) Monday in a deal worth up to $570 million. Medivation is paying $410 million upfront for talazoparib, which is currently in phase three testing for advanced or metastatic breast cancer involving germline mutations of the BRCA gene. If the drug succeeds, BioMarin is due up to $160 million in milestone payments along with Scalper1 News
Scalper1 News